title: Targeting calcium/calmodulin-dependence kinase I and II as a potential anti-proliferation remedy for endometrial carcinomas.
abstract: Calcium/calmodulin-dependent kinase (CaMK) I and II expression in endometrial cancer cells correlates with the malignant potential of this tumor, and CaMKI and II are potential therapeutic targets in endometrial cancer. CaMKI and II expression was significantly associated with PCNA-labeling index, clinical stage, histological grade, the presence of invasion to greater than one-half the myometrium, and clinical outcome. All endometrial cancer cell lines examined were sensitive to the growth-inhibitory effect of KN-93, a membrane-permeant CaMKs-selective inhibitor that is competitive with calmodulin. KN-93 induced the G0/G1 arrest and apoptosis, rising hopes that KN-93 may become a useful treatment for endometrial cancers.
authors.affiliation: Department of Obstetrics and Gynecology, Oita University Faculty of Medicine, 1-1 Idaigaioka, Hasama-machi, Yufu-shi, Oita, Japan. takai@med.oita-u.ac.jp
authors.forename: Noriyuki
authors.initials: N
authors.lastname: Takai
authors.forename: Tami
authors.initials: T
authors.lastname: Ueda
authors.forename: Kaei
authors.initials: K
authors.lastname: Nasu
authors.forename: Satoko
authors.initials: S
authors.lastname: Yamashita
authors.forename: Mayo
authors.initials: M
authors.lastname: Toyofuku
authors.forename: Hisashi
authors.initials: H
authors.lastname: Narahara
mesh_terms: D000970:Antineoplastic Agents / Q000494:pharmacology*; D017209:Apoptosis / Q000187:drug effects; D001596:Benzylamines / Q000494:pharmacology*; D054729:Calcium-Calmodulin-Dependent Protein Kinase Type 1 / Q000037:antagonists & inhibitors* / Q000378:metabolism; D054732:Calcium-Calmodulin-Dependent Protein Kinase Type 2 / Q000037:antagonists & inhibitors* / Q000378:metabolism; D002147:Calmodulin / Q000378:metabolism; D002453:Cell Cycle / Q000187:drug effects / Q000502:physiology; D045744:Cell Line, Tumor; D049109:Cell Proliferation / Q000187:drug effects*; D016889:Endometrial Neoplasms; D005260:Female; D006801:Humans; D013449:Sulfonamides / Q000494:pharmacology*; D000096926:Benzenesulfonamides
chemical_list: D000970:Antineoplastic Agents; D001596:Benzylamines; D054729:Calcium-Calmodulin-Dependent Protein Kinase Type 1; D054732:Calcium-Calmodulin-Dependent Protein Kinase Type 2; D002147:Calmodulin; D013449:Sulfonamides; C072105:KN 93; D000096926:Benzenesulfonamides; C517596:CAMK1 protein, human